Lonafarnib

Soft Tissue Sarcoma

Emory UniversitySmall moleculePhase 1Dormant

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 81/ 100

Competitive context

104 Active assets in the Soft Tissue Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Palbociclib Brown University	Phase 2	BB
FILGRASTIM University of California, Irvine	Phase 3	BB
Inno-206 GI Innovation, Inc.	Phase 3	BB
Eloxatin OHSU Knight Cancer Institute	Phase 2	BB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 2	BB

View all 50 →

Same molecule, other indications

Lonafarnib is also rated in:

Hutchinson-Gilford progeria syndromeDormant

B

Indicative ·

58 / 100

metastatic neoplasmDormant

B

Indicative ·

57 / 100

renal pelvis/ureter urothelial carcinomaDormant

CCC

Indicative ·

55 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.